14 completed, 5 terminated, 1 active not recruiting, 1 recruiting. 12 Phase 1, 12 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 4.
Follow PLX3397: new trials by email Literature Review of PLX3397 trials Research Report on PLX3397
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 2 | Completed | Daiichi Sankyo Co., Ltd. | 9 | 2021-03-15 | 2026-06-24 |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 4 | Completed | Daiichi Sankyo | 32 | 2020-10-20 | 2024-12-30 |
| A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 3 | Active not recruiting | Daiichi Sankyo Co., Ltd. | 40 | 2020-09-25 | 2026-06-26 |
| A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma PLX3397 - Melanoma | Not applicable | Completed | Daiichi Sankyo Co., Ltd. | 6 | 2017-01-31 | 2026-01-13 |
| Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers Pexidartinib, Durvalumab - Colorectal Cancer, Pancreatic Cancer | Phase 1 | Completed | Centre Leon Berard | 48 | 2016-06-01 | 2021-09-05 |
| PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors PLX3397, sirolimus - Sarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 / Phase 2 | Terminated | Gulam Manji | 39 | 2015-11-04 | 2025-03-21 |
| PLX3397 KIT in Acral aNd mucOsal Melanoma PLX3397 - Malignant Melanoma | Phase 2 | Completed | The Christie NHS Foundation Trust | 7 | 2015-10-01 | 2021-08-12 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors PLX3397, Pembrolizumab - Melanoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 78 | 2015-07-02 | 2020-03-05 |
| PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397 - Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 8 | 2015-06-01 | 2020-10-06 |
| Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) Pexidartinib, Placebo - Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath | Phase 3 | Completed | Daiichi Sankyo | 120 | 2015-05-11 | 2022-05-11 |
| CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors CGT9486, Pexidartinib, Sunitinib - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Completed | Cogent Biosciences, Inc. | 51 | 2015-03-06 | 2025-02-14 |
| A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma PLX3397, vemurafenib - V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma | Phase 1 | Terminated | Daiichi Sankyo | 13 | 2013-11-05 | 2020-05-28 |
| A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma PLX3397, Radiation Therapy, Temozolomide - Patients With Newly Diagnosed Glioblastoma | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 65 | 2013-07-18 | 2020-06-30 |
| Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer PLX3397, Eribulin - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Hope Rugo, MD | 67 | 2012-07-12 | 2020-07-17 |
| Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) PLX3397 - Prostate Cancer | Phase 2 | Terminated | Daiichi Sankyo | 6 | 2012-05-25 | 2020-03-04 |
| Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors PLX3397, Paclitaxel - Solid Tumors | Phase 1 | Completed | Daiichi Sankyo | 74 | 2012-05-01 | 2020-07-16 |
| A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma PLX3397 - Recurrent Glioblastoma | Phase 2 | Terminated | Daiichi Sankyo | 38 | 2011-12-03 | 2020-03-03 |
| Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) PLX3397 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 90 | 2011-11-21 | 2020-03-02 |
| Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma PLX3397 - Hodgkin Lymphoma | Phase 2 | Completed | Daiichi Sankyo | 20 | 2011-03-03 | 2020-06-30 |
| Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate PLX3397 - Rheumatoid Arthritis | Phase 1 | Withdrawn | Plexxikon | 2010-05-01 | 2015-03-17 |
Showing 20 of 22. Sign in to see all of them.
Giant Cell Tumor of Tendon Sheath (4) · Melanoma (3) · Breast Neoplasms (2) · Gastrointestinal Stromal Tumors (2) · Glioblastoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Synovitis, Pigmented Villonodular (2) · Arthritis, Rheumatoid (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Hemangiosarcoma (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1)
Daiichi Sankyo (11) · Daiichi Sankyo Co., Ltd. (3) · Barbara Ann Karmanos Cancer Institute (1) · Centre Leon Berard (1) · Cogent Biosciences, Inc. (1) · Gulam Manji (1) · Hope Rugo, MD (1) · Plexxikon (1) · QuantumLeap Healthcare Collaborative (1) · The Christie NHS Foundation Trust (1)
United States (17) · France (3) · Australia (2) · China (2) · Germany (2) · Hungary (2) · Italy (2) · Netherlands (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Canada (1) · Denmark (1) · Japan (1) · Poland (1)
Alexander Perl, MD (1) · Catherine Smith, MD (1) · Elisabeth I. Heath, M.D. (1) · Eunice Wang, MD (1) · Gail Roboz, MD (1) · Gulam A. Manji, MD (1) · Hope S. Rugo, MD (1) · Jessica Sachs, MD (1) · John Pagel, MD, PhD (1) · Laura Esserman, MD, MBA (1) · Mark Levis, MD, PhD (1)
PMID 33289960, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 24101040, PMID 24552317, PMID 26222558, PMID 27041409, PMID 27406346, PMID 27406347, PMID 28851423, PMID 31229240, PMID 32031889, PMID 32053137, PMID 32330242, PMID 32450725, PMID 32701140, PMID 32755241, PMID 34236401, PMID 34321280, PMID 34529000, PMID 34716196, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36001000, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38266104, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 40841499, PMID 41879562, PMID 42132251, PMID 42530945
2014 (1), 2015 (1), P30CA022453 (1)